

Peter J Greasley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3606838/publications.pdf>

Version: 2024-02-01

13
papers

572
citations

1307594
7
h-index

1125743
13
g-index

13
all docs

13
docs citations

13
times ranked

998
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 541-554. | 2.0 | 2 |
| 2 | Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1578-1587. | 4.4 | 11 |
| 3 | Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. <i>PLoS ONE</i> , 2022, 17, e0269970. | 2.5 | 2 |
| 4 | Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression. <i>Kidney360</i> , 2021, 2, 105-113. | 2.1 | 10 |
| 5 | Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPAâ€œCHF Study Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 636-648. | 2.0 | 9 |
| 6 | Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 76-91. | 2.5 | 8 |
| 7 | Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic Diversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4157-e4168. | 3.6 | 4 |
| 8 | Development of Human Target Validation Classification that Predicts Future Clinical Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 255-261. | 2.5 | 1 |
| 9 | The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 339-346. | 0.7 | 28 |
| 10 | Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 479-487. | 4.4 | 336 |
| 11 | Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. <i>Science Translational Medicine</i> , 2018, 10, . | 12.4 | 91 |
| 12 | Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1295-F1306. | 2.7 | 46 |
| 13 | Deletion of Cpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation. <i>PLoS ONE</i> , 2016, 11, e0167965. | 2.5 | 24 |